Skip to main content
PLOS One logoLink to PLOS One
. 2021 Feb 11;16(2):e0246715. doi: 10.1371/journal.pone.0246715

Evaluating the effect of Chinese control measures on COVID-19 via temporal reproduction number estimation

Duanbing Chen 1,2, Tao Zhou 1,3,*
Editor: Abdallah M Samy4
PMCID: PMC7877593  PMID: 33571273

Abstract

Control measures are necessary to contain the spread of serious infectious diseases such as COVID-19, especially in its early stage. We propose to use temporal reproduction number an extension of effective reproduction number, to evaluate the efficacy of control measures, and establish a Monte-Carlo method to estimate the temporal reproduction number without complete information about symptom onsets. The province-level analysis indicates that the effective reproduction numbers of the majority of provinces in mainland China got down to < 1 just by one week from the setting of control measures, and the temporal reproduction number of the week [15 Feb, 21 Feb] is only about 0.18. It is therefore likely that Chinese control measures on COVID-19 are effective and efficient, though more research needs to be performed.

Introduction

Emerged from Wuhan City, the novel coronavirus diseases rapidly expanded since December 2019. Early analyses indicated that COVID-19 has middle-to-high transmissibility, with preliminary estimation of basic reproduction number R0 lying in the range [2.0, 4.0], e.g., 1.4-3.9 [1], 2.47-2.86 [2] and 2.8-3.9 [3]. After a period of stealthy spread, on 20 January 2020, COVID-19 was identified as a B-type infectious disease in China, and the control measures were set according to the standard of A-type infectious disease. Roughly speaking, 21 January 2020 can be considered as the starting date of control, on which every province in China took COVID-19 spread as an emergency event and launched strong control measures according to directives of the central government. These control measures have achieved remarkable success, with daily number of confirmed cases quickly decreasing after a short expansion lasting about two weeks from 21 January 2020.

In general, basic reproduction number R0 can be used to characterize the transmissibility of infectious diseases. It refers to the average number of individuals who will be infected by one infected case in a fully susceptible population without external interventions. Without control, infectious diseases will gradually die out if R0 < 1, will spread exponentially and become epidemics if R0 > 1, and will become endemic in the population if R0 ≈ 1. The basic reproduction number is far different for different infectious diseases, for example, Zika: 1.4-6.6 [4], H1N1: 1.4-3.1 [5], dengue: 1.52-3.90 [6], Ebola: 1.3-2.7 [7], SARS: 2.2-3.7 [8], MERS: 2.0-6.7 [9], smallpox: 3.5-6.0 [10], measles: 12-18 [11], pertussis: 12-17 [12], etc. Usually, it is difficult to directly measure the value of R0 since R0 is affected by numerous biological, sociobehavioral, and environmental factors [13], and thus statistical models are widely applied to estimate R0 [1417].

We always assume the population is fully susceptible without control measures in estimating the value of R0. However, during the epidemic spreading, various control measures will be introduced to contain the spread, so we should adopt time-related reproduction number to quantify the temporal situation of the spread and the control efficacy. The most intuitive metric is the effective reproduction number Rt, which is defined as the average number of secondary cases infected by an infected case with symptom onset at day t. Various methods to estimate Rt under different scenarios were proposed in the literature [1823].

If complete information about who infects whom is known, Rt can be determined by simply counting secondary cases. However, tracing information is usually incomplete or not timely available, and thus statistical approaches are required. Willinga and Teunis [24] proposed a likelihood-based method to estimate Rt from the epidemic curve and the distribution of generation intervals, which works only for the period in which all secondary cases would have been detected, thus resulting in a time lag about 19 days for COVID-19 (95th percentile of the distribution of generation intervals [1]). By accounting for yet unobserved secondary cases via Bayesian inference, Cauchemez et al. [25] extended the Wallinga-Teunis method to provide real-time estimates of Rt.

In real world, the situation may be even worse, where not only the complete tracing records, but also the full epidemic curves are unknown. In order to deal with such situation, we proposed a Monte-Carlo method to estimate the full epidemic curve by using a small number of cases with known symptom onsets, and then to estimate the reproduction number.

Materials and methods

Estimation of Rt

Distribution of generation intervals and epidemic curve are two main inputs to estimate Rt, where generation intervals refer to time intervals between symptom onsets of index cases and their infected cases, and the epidemic curve records the number of cases with symptom onsets at each day. According to the empirical observations [1], the distribution of generation intervals, q(tg), can be approximated by a Gamma distribution [26]:

q(tg)=βαΓ(α)tgα-1e-βtg(tg>0), (1)

where α ≈ 4.866 is the shape parameter and β ≈ 0.649 is the inverse scale parameter. Given two cases i and j with symptom onset times being ti and tj, the likelihood that case i is infected by case j (ti > tj) is thus

ρij=q(ti-tj)k,ti>tkq(ti-tk). (2)

Wallinga and Teunis [24] suggested that the expected number of secondary cases infected by case j can be estimated by the sum of likelihoods, as

Rj=i,ti>tjρij. (3)

The effective reproduction number can thus be estimated as

Rt=1|Ct|jCtRj, (4)

where Ct is the set of cases with symptom onsets at day t. Obviously, Rt = Rj if jCt since in the Wallinga-Teunis method, cases with the same symptom onset time have the same expected number of secondary cases.

We further consider the task to calculate the effective reproduction number Rt given the last known onset time T. Obviously, only if T > t, this task is possible. If Tt+tgmax with tgmax denoting the maximum generation interval, we can directly apply the Wallinga-Teunis method. However, if t<T<t+tgmax, we need to introduce an additional step with Bayesian inference [25]. Assuming the mean number of secondary cases infected by a case with symptom onset at day t can be decomposed by two parts as

Rt=Rt-(T)+Rt+(T), (5)

where Rt-(T) and Rt+(T) are the mean numbers of secondary cases with symptom onsets before or at T and after T, respectively. The value of Rt-(T) can be directly estimated by using the Wallinga-Teunis method, and thus we can infer the effective reproduction number as

Rt=Rt-(T)tg=1T-tq(tg). (6)

Temporal reproduction number

In this paper, we also consider a slightly different reproduction number, called the temporal reproduction number, to include the period-dependent metric R[t1,t2](t1t2) that is defined as the average number of secondary cases infected by an infected case with symptoms onset during the time period [t1, t2] [27]. Accordingly, Rt is a special case of R[t1,t2] when t1 = t2 = t. Similar to the effective reproduction number, the temporal reproduction number can be estimated as

R[t1,t2]=1|C[t1,t2]|jC[t1,t2]Rj, (7)

where C[t1,t2] is the set of cases with symptom onsets in the range [t1, t2].

Inferring the epidemic curve

For both methods proposed by Willinga and Teunis [24] and Cauchemez et al. [25], the epidemic curve must be given so as to estimate the effective reproduction number or temporal reproduction number. However, we usually face an even-worse condition about data accessibility, where not only the complete tracing records, but also the full epidemic curve is unknown. For example, the number of confirmed cases of COVID-19 for each province in mainland China is made public every day, while the symptom onset of each case is not reported by Chinese CDC. Using the collected records with both known symptom onsets and confirmed dates from scattered reports, we can obtain the empirical distribution of time intervals between symptom onsets and laboratory confirmations, say p(tΔ). Then, we develop a Monte-Carlo method to infer the epidemic curve. Given a case i confirmed at day t(i), sample a time interval tΔ(i) according to the distribution p(tΔ) and set i′s symptom onset as ti=t(i)-tΔ(i). Specifically, the uniform stochastic model U(0, 1) is used to sample time intervals between symptom onsets and laboratory confirmations. that is, we use uniform stochastic model U(0, 1) to return a random number z between 0 and 1, and then the time interval tΔ(i) is defined by the constrain P(tΔ(i)-1)<zP(tΔ(i)), where P(tΔ) is the cumulative distribution corresponding to p(tΔ). Combining it with the methods mentioned above, we can estimate effective reproduction number and temporal reproduction number, and thus evaluate the efficacy of control measures.

In this paper, we implement S = 10000 independent runs to obtain the mean values and confidence intervals. Furthermore, we take the interval time between the symptom onsets and laboratory confirmations as the statistic variable X, and use K-S test [28] to estimate the marginal error ε, as

ε=Dασ, (8)
Dα=0.888/S, (9)
σ=1Si=1SXi2-(1Si=1SXi)2, (10)

where S is the sample size (i.e., the number of independent runs), σ is the standard deviation, α is the significance level, and Dα is the critical value. In our work, the marginal error is ε = 0.0379 subject to α = 0.05 and S = 10000.

In summary, the proposed method can be decomposited into three parts, namely, inputs, output and processes. The inputs include the distribution of generation intervals, the symptom onsets of some cases, and the laboratory confirmations of all cases. The output of the model is the estimated effective reproduction number Rt. In the processes, we estimate the distribution of intervals between symptom onsets and laboratory confirmations based on the cases with known symptom onsets and laboratory confirmations and apply the Monte Carlo sampling method to estimate the symptom onsets of other cases based on their laboratory confirmations. So that, the epidemic curve of all cases can be approximately obtained. Finally, the effective reproduction number is estimated according to the epidemic curve and the distribution of generational intervals. The inputs, output and processes of the proposed method are illustrated in Fig 1.

Fig 1. The inputs, output and processes of the proposed method.

Fig 1

Results

We have collected all 76936 confirmed cases reported in official websites, which are the known ensemble for the mainland China from 11 January 2020 to 22 February 2020. The detailed quantitative information of daily number of confirmed cases is from National Health Commission of China whose URL address is http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml. A very small fraction (4.74%) of these confirmed cases (i.e. 3650 cases) with known symptom onsets are collected from the six provinces that have reported such information. Since all provinces except Hubei applied almost the same control measures, the samples are representative. The confirmed cases for Tibet and Qinghai are only 1 and 15, so we do not analyze these two provinces.

Based on the six provinces with records of symptom onsets, we have checked that individual distributions are close to each other and can be well resembled by the synthesized distribution (see Fig 2).

Fig 2. Comparison between the synthesized distribution of time intervals between symptom onsets and confirmations (red solid line) and individual distributions of Sichuan, Guangdong, Anhui, Henan, Jiangxi and Zhejiang (gray data points).

Fig 2

Moreover, as shown in Fig 3, the synthesized distribution p(tΔ) can be well fitted by a translational Weibull distribution [29]:

p(tΔ)=αβ(tΔ+γβ)α-1e-(tΔ+γβ)α, (11)

where the shape parameter α ≈ 1.48, the scale parameter β ≈ 7.03, and the translational parameter γ = 0.10. We introduce the translational parameter because some cases are confirmed immediately so p(0) > 0, while the original Weibull distribution gives p(0) = 0 for any shape parameter and scale parameter.

Fig 3. Comparison between the synthesized distribution of time intervals between symptom onsets and confirmations (red circles) and the fitting curve (blue curve) that obeys the translational Weibull distribution (11).

Fig 3

The province-level results are shown in Table 1. These results demonstrate the impressive achievement by control measures, namely Rt for the majority of provinces decreased to < 1 within one week from the starting date of control. Even for Hubei, the epidemic was under control (Rt < 1) in just two weeks. In addition, within a month, the average temporal reproduction number over all provinces already decayed to 0.18, a very small value corresponding to a dying phase of the epidemic. Fig 4 reports the estimated Rt for each province from 10 January 2020 to 21 February 2020 by using the present method.

Table 1. Results for all provinces in mainland China except Tibet and Qinghai, where the confirmed cases are too few to do statistics.

For each province, we show: (i) the number of cumulated confirmed cases by 22 February 2020; (2) the date t* when Rt got below 1; and (iii) the temporal reproduction number during the last week [15 February 2020, 21 February 2020]. The results are averaged over 10000 independent runs.

Province Number of cumulated confirmed cases Date t* when Rt below 1 Temporal reproduction number of the last week
Fujian 298 2020/1/23 0.1365
Liaoning 121 2020/1/23 0.0053
Yunnan 174 2020/1/23 0.2039
Shanghai 335 2020/1/24 0.1967
Zhejiang 1205 2020/1/24 0.2895
Chongqing 573 2020/1/24 0.2463
Beijing 399 2020/1/25 0.2493
Gansu 91 2020/1/25 0
Guangdong 1342 2020/1/25 0.1088
Guangxi 249 2020/1/25 0.3232
Hunan 1016 2020/1/25 0.1321
Shaanxi 245 2020/1/25 0.3002
Sichuan 526 2020/1/25 0.1757
Henan 1271 2020/1/26 0.0848
Nei Monggol 75 2020/1/26 0.3176
Ningxia 71 2020/1/26 0.0146
Shanxi 132 2020/1/26 0.278
Shandong 754 2020/1/27 0.4977
Anhui 989 2020/1/27 0.082
Hainan 168 2020/1/27 0.3487
Jiangsu 631 2020/1/27 0.0901
Jiangxi 934 2020/1/27 0.0556
Tianjin 135 2020/1/27 0.4241
Hebei 311 2020/1/28 0.1736
Jilin 91 2020/1/28 0.1651
Guizhou 146 2020/1/29 0.0156
Heilongjiang 480 2020/1/29 0.1307
Xinjiang 76 2020/1/30 0.132
Hubei 64287 2020/2/2 0.0491

Fig 4. Effective reproduction numbers for all provinces in mainland China from 10 January 2020 to 21 February 2020.

Fig 4

The results are averaged over 10000 independent runs, and the cyan areas denote the 95% confidence intervals. In each run, the Monte-Carlo sampling method is applied to infer the symptom onsets. The gray shadows emphasize the situations where the epidemic is under control (Rt < 1).

Furthermore, we propose a so-called 5Γ-model with N = 1, 000, 000 individuals to illustrate the reliability of the present method. The spreading starts with 10 initially infected individuals, and all infected and susceptible individuals are fully mixed. In the simulation, in each time step (i.e., a day), the number of contacted individuals of each infected case is independently drawn from the Gamma distribution Γ1. For each contact between an infected individual and a susceptible individual, the infected probability is independently drawn from the Gamma distribution Γ2. The time intervals between symptom onsets and laboratory confirmations obey the Gamma distribution Γ3. The generation intervals obey the Gamma distribution Γ4. The time intervals between laboratory confirmations and removals from the dynamics (i.e., died, recovered, effectively isolated, etc.) obey the Gamma distribution Γ5. The means and variances of all the five Gamma distributions are listed in Table 2.

Table 2. The means and variances of the five Gamma distributions used in the simulation model.

Distribution Mean Variance
Γ1 15 10
Γ2 0.009 1.8 × 10 −6
Γ3 5 2
Γ4 7.5 3.4
Γ5 20 8

We assume that the symptom onsets of 20% randomly selected confirmed cases are known, and the laboratory confirmations of all cases are known. The effective reproduction number Rt can be directly counted by the simulation model as all transmission chains are known. We compare the accuracy of our method and that of the Wallinga-Teunis method, with simulation results being the benchmark. As shown in Fig 5, the effective reproduction numbers estimated by our method are very close to the benchmark values and remarkably more accurate than those obtained by the Wallinga-Teunis method. We have also checked that our estimations work well subject to other reasonable settings of distributions and parameters.

Fig 5. The comparison of effective reproduction numbers directly counted based on the simulation results (blue squares) and estimated by the Wallinga-Teunis method (black triangles) and our method (red circles).

Fig 5

The results obtained by the Wallinga-Teunis method and our method are both averaged over 10000 independent runs.

Discussion

A Monte-Carlo method is proposed to infer the epidemic curve, and then estimate the temporal reproduction number. Our results suggest that Chinese control measures are likely to be effective and efficient, with daily number of confirmed cases quickly decreasing after a short expansion lasting about two weeks from 21 January 2020. By introducing a Monte-Carlo method to estimate the symptom onsets of confirmed cases based on a small number of cases with known symptom onsets, our method can utilize the information of all cases to calculate the effective reproduction number. In comparison, the Wallinga-Teunis method can only make use of the cases with both known symptom onsets and laboratory confirmations. As shown in Fig 5, our method produces obviously more accurate results than the Wallinga-Teunis method. One underlying assumption in our method is that the small number of samples are representative of all cases. This is a reasonable assumption for mainland China since control measures in different provinces are very much the same, all executing directives from the central government. However, in general, if the samples and the inferred cases are in different spreading stages or different areas, the reliability of the present method has to be carefully checked before any applications. For example, in US, cases in a few states cannot represent the whole country since different states may adopt different controlling strategies and launch different control measures.

The distribution p(tΔ) is not stable, usually with smaller and smaller mean and standard deviation in the progress of an epidemic [18]. Fig 6 compares the estimates of effective reproduction numbers by the true and inferred records of symptom onsets for the six provinces with known symptom onsets. At the very beginning, the estimates from inferred data are smaller than the ones from true records, but they are getting closer and closer and show almost the same t* in the later stage. Indeed, we still overestimate the reproduction number in the early stage, because a large fraction of cases (except Hubei) are importations [18, 30]. Fortunately, the present method shows accordance with the one accounting for importations. For example, Rt of the three example provinces (Guangdong, Hunan and Shandong) approach 1 at 23 January 2020, 26 January 2020 and 30 January 2020 by the method in [30] and at 25 January 2020, 25 January 2020 and 27 January 2020 by the present method. In a word, this method can be further improved by considering importations [18, 30] and using Markov-Chain Monte-Carlo algorithm based on independent transmission assumption [3133].

Fig 6. Comparison between the estimates of effective reproduction numbers by the true and inferred records of symptom onsets.

Fig 6

The solid blue curves and cyan areas respectively denote the average values and 95% confidence intervals obtained by 10000 independent runs according to the inferred data. The red circles represent the results obtained by the true records. The gray shadows emphasize the situations where the epidemic is under control (Rt < 1). The six plots are results for Sichuan, Guangdong, Anhui, Henan, Jiangxi and Zhejiang.

Government-led actions likely played a role in the reduction of new COVID-19 cases. In order to block transmission and reduce public health hazards, the “five early” measures, namely “early detection, early report, early investigation, early isolation and early treatment”, are implemented. Early detection.—Rapid detection and diagnosis to promote the timely and effective management of confirmed and suspected cases. Early report.—Immediate report to the disease control department about confirmed and suspected cases to start investigation and treatment as soon as possible. Early investigation.—Quick epidemiological investigation on the exposure and detailed contacts of confirmed and suspected cases. Through such investigation, we can find out the transmission chain of each case, so as to comprehensively manage all possible infected individuals related to each case. Early isolation.—All confirmed and suspected cases, as well as their close contacts will be isolated as soon as possible. Early treatment.—Quick providing of proper treatment (symptomatic treatment, supportive treatment, antiviral treatment via traditional Chinese medicine, etc.) to prevent the development of symptom. To efficiently and effectively implement the “five early” measures, some advanced information techniques are employed to trace the epidemic spreading. For example, in many cities, the QR codes [34, 35] (similar to these used for online payments) are posted in public transport means (buses, subway stations, taxies, etc.), places with possible crowds (supermarkets, bazaars, restaurants, office buildings, etc.) and places worth particular attention (drugstores). People are asked to scan the codes before entering, so the administrators can get the corresponding check-in records with identifications (mobile phone ID). Therefore, if a person is laboratory confirmed or identified as a suspected case, the administrators will know immediately and exactly the persons who have possible contacts with this case by simply searching the check-in records. This operation is completely automatic with private information being protected if an individual is not laboratory confirmed, suspected or having close contacts with the above two kinds of people (even one is confirmed, her/his personal information is only used in fighting the disease). Fig 7 illustrates an example of the QR codes, which was posted in a bus in Chengdu City of Sichuan Province, and people are required to scan the code before getting on the bus. Therefore, if a confirmed or suspected case has taken this bus, we can immediately find out people who have also taken this bus in the same time period. This is in our opinion a simple but perfect tool in the epidemiological perspective to efficiently and effectively block the spread through communities.

Fig 7. Illustration of an example of the QR codes to trace the epidemic in mainland China.

Fig 7

This is the one posted in a public bus in Chengdu City. In the bottom, a Chinese character followed by A11345 is the plate number of this bus, and the character is the abbreviation of Sichuan Province.

Supporting information

S1 Dataset

(RAR)

Acknowledgments

We thank Yan Wang, Wei Bai and Min Wang for data collection, Qin Gu for developing the check-in system via scanning the QR codes and sharing some representative QR codes with us, and Quan-Hui Liu for helpful discussion.

Data Availability

The detailed information of daily number of confirmed cases is from National Health Commission of China whose URL address is http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml. And all dataset files are available from email dbchen@uestc.edu.cn The authors of the present study had no special access privileges in accessing the datasets from the National Health Commission of China which other interested researchers would not have.

Funding Statement

This work was partially supported by the National Natural Science Foundation of China (61673085, 11975071, 61433014) and by the Science Strength Promotion Programme of UESTC(Y03111023901014006). There was no additional external funding received for this study.

References

  • 1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. 2020;382:1199–1207. 10.1056/NEJMoa2001316 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020;395:689–697. 10.1016/S0140-6736(20)30260-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Zhou T, Liu QH, Yang Z, Liao J, Yang K, Bai W, et al. Preliminary prediction of the basic reproduction number of the Wuhan novel coronavirus 2019–nCoV. J Evid Based Med. 2020;13:3–7. 10.1111/jebm.12376 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Lessler J, Chaisson LH, Kucirka LM, Bi Q, Grantz K, Salje H, et al. Assessing the global threat from Zika virus. Science. 2016;353:aaf8160 10.1126/science.aaf8160 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Roberts MG, Nishiura H. Early estimation of the reproduction number in the presence of imported cases: pandemic influenza H1N1-2009 in New Zealand. PLoS One. 2011;6(5):e17835 10.1371/journal.pone.0017835 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Sanches RP, Massad E. A comparative analysis of three different methods for the estimation of the basic reproduction number of dengue. Infect Dis Model. 2016;1(1):88–100. 10.1016/j.idm.2016.08.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Sherry T, Oscar PL, Carlos CC. Temporal variations in the effective reproduction number of the 2014 west Africa ebola outbreak. PLoS Curr. 2014;6 10.1371/currents.outbreaks.9e4c4294ec8ce1adad283172b16bc908 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Riley S, Fraser C, Donnelly CA, Ghani AC, Abu-Raddad LJ, Hedley AJ, et al. Transmission dynamics of the etiological agent of SARS in Hong Kong: Impact of public health interventions. Science. 2003;300(5627):1961–1966. 10.1126/science.1086478 [DOI] [PubMed] [Google Scholar]
  • 9. Majumder MS, Rivers C, Lofgren E, Fisman D. Estimation of MERS-coronavirus reproductive number and case fatality rate for the spring 2014 Saudi Arabia outbreak: insights from publicly available data. PLoS Curr. 2014;6 10.1371/currents.outbreaks.98d2f8f3382d84f390736cd5f5fe133c [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Eichner M, Dietz K. Transmission potential of smallpox: estimates based on detailed data from an outbreak. Am J Epidemiol. 2003;158(2):110–117. 10.1093/aje/kwg103 [DOI] [PubMed] [Google Scholar]
  • 11. Guerra FM, Bolotin S, Lim G, Heffernan J, Deeks SL, Li Y, et al. The basic reproduction number (R0) of measles: a systematic review. Lancet Infect Dis. 2017;17(12):e420–e428. 10.1016/S1473-3099(17)30307-9 [DOI] [PubMed] [Google Scholar]
  • 12. Anderson RM, May RM. Directly transmitted infections diseases: control by vaccination. Science. 1982;215(4536):1053–1060. 10.1126/science.7063839 [DOI] [PubMed] [Google Scholar]
  • 13. Delamater PL, Street EJ, Leslie TF, Yang YT, Jacobsen KH. Complexity of the basic reproduction number (R0). Emerg Infect Dis. 2019;25(1):1–4. 10.3201/eid2501.171901 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Perasso A. An introduction to the basic reproduction number in mathematical epidemiology. ESAIM: Proceedings and Surveys. 2018;62:123–138. 10.1051/proc/201862123 [DOI] [Google Scholar]
  • 15. Allen LJS, Driessche PV. The basic reproduction number in some discrete-time epidemic models. J Differ Equ Appl. 2008;14(10-11):1127–1147. 10.1080/10236190802332308 [DOI] [Google Scholar]
  • 16. Magal P, Webb GF, Wu Y. On the basic reproduction number of reaction-diffusion epidemic models. SIAM J Appl Math. 2019;79(1):284–304. 10.1137/18M1182243 [DOI] [Google Scholar]
  • 17. Roberts MG, Heesterbeek JAP. Model-consistent estimation of the basic reproduction number from the incidence of an emerging infection. J Math Biol. 2007;55(5-6):803–816. 10.1007/s00285-007-0112-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Cowling BJ, Lau MSY, Ho LM, Chuang SK, Tsang T, Liu SH, et al. The effective reproduction number of pandemic influenza: prospective estimation. Epidemiology. 2010;21(6):842–846. 10.1097/EDE.0b013e3181f20977 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Codeço CT, Villela DAM, Coelho FC. Estimating the effective reproduction number of dengue considering temperature-dependent generation intervals. Epidemics. 2018;25:101–111. 10.1016/j.epidem.2018.05.011 [DOI] [PubMed] [Google Scholar]
  • 20. Lai A, Bergna A, Acciarri C, Galli M, Zehender G. Early phylogenetic estimate of the effective reproduction mumber of SARS-CoV-2. J Med Virol. 2020;92:675–679. 10.1002/jmv.25723 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Tariq A, Roosa K, Mizumoto K, Chowell G. Assessing reporting delays and the effective reproduction number: The Ebola epidemic in DRC, May 2018–January 2019. Epidemics. 2019;26:128–133. 10.1016/j.epidem.2019.01.003 [DOI] [PubMed] [Google Scholar]
  • 22. Zhao S, Musa SS, Hebert JT, Cao P, Ran J, Meng J, et al. Modelling the effective reproduction number of vector-borne diseases: the yellow fever outbreak in Luanda, Angola 2015–-2016 as an example. Peer J. 2020;8:e8601 10.7717/peerj.8601 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Chong YC. A novel method for the estimation of a dynamic effective reproduction number (Dynamic-R) in the CoViD-19 outbreak. medRxiv. 2020; 10.1101/2020.02.22.20023267. [DOI] [Google Scholar]
  • 24. Wallinga J, Teunis P. Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures. Am J Epidemiology. 2004;160(6):509–516. 10.1093/aje/kwh255 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Cauchemez S, Boëlle PY, Donnelly CA, Ferguson NM, Thomas G, Leung GM, et al. Real-time estimates in early detection of SARS. Emerg Infect Dis. 2006;12(1):110–113. 10.3201/eid1201.050593 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Stacy EW. A generalization of the Gamma distribution. Ann Math Stat. 1962;33(3):1187–1192. 10.1214/aoms/1177704481 [DOI] [Google Scholar]
  • 27. Cauchemez S, Boëlle PY, Thomas G, Valleron AJ. Estimating in real time the efficacy of measures to control emerging communicable diseases. Am J Epidemiology. 2006;164(6):591–597. 10.1093/aje/kwj274 [DOI] [PubMed] [Google Scholar]
  • 28. Crutcher HL. A note on the possible misuse of the Kolmogorov-Smirnov test. J Appl Meteoro. 1975;14(8):1600–1602. [DOI] [Google Scholar]
  • 29. Rinne H. The Weibull distribution: a handbook. CRC Press; 2008. [Google Scholar]
  • 30. Zhang J, Litvinova M, Wang W, Wang Y, Deng X, Chen X, et al. Evolving epidemiology of novel coronavirus diseases 2019 and possible interruption of local transmission outside Hubei Province in China: a descriptive and modeling study. Lancet Infect Dis. 2020;20(7):793–802. 10.1016/S1473-3099(20)30230-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. White LF, Pagano M. A likelihood-based method for real-time estimation of the serial interval and reproductive number of an epidemic. Statistics in Medicine. 2008;27(16):2999–3016. 10.1002/sim.3136 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Liu QH, Ajelli M, Aleta A, Merler S, Moreno Y, Vespignani A. Measurability of the epidemic reproduction number in data-driven contact networks. Proc Natl Sci Acad USA. 2018;115(50):12680–12685. 10.1073/pnas.1811115115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Liu QH, Bento AI, Yang KX, Zhang H, Yang XH, Merler S, et al. The COVID-19 outbreak in Sichuan, China: epidemiology and impact of interventions. PLoS Comput Bio. 2020;16(12):e1008467 10.1371/journal.pcbi.1008467 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Xu M, Su H, Li Y, Li X, Liao J, Niu J, et al. Stylized aesthetic QR code. IEEE Trans Multimedia. 2019;21(8):1960–1970. 10.1109/TMM.2019.2891420 [DOI] [Google Scholar]
  • 35. Focardi R, Luccio FL, Wahsheh HAM. Usable security for QR code. J Inf Secur Appl. 2019;48:102369. [Google Scholar]

Decision Letter 0

Abdallah M Samy

3 Jul 2020

PONE-D-20-11733

Chinese Control Efficacy on COVID-19

PLOS ONE

Dear Dr. Zhou,

Thank you very much for submitting your manuscript "Chinese Control Efficacy on COVID-19" (#PONE-D-20-11733) for review by PLOS ONE. As with all papers submitted to the journal, your manuscript was fully evaluated by academic editor (myself) and by independent peer reviewers. The reviewers appreciated the attention to an important health topic, but they raised substantial concerns about the paper that must be addressed before this manuscript can be accurately assessed for meeting the PLOS ONE criteria. Therefore, if you feel these issues can be adequately addressed, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. We can’t, of course, promise publication at that time.

Please submit your revised manuscript by Aug 16 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Abdallah M. Samy, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In the Methods, please clarify how information about the daily number of confirmed cases for all provinces in mainland China from 11 January 2020 to 22 February 2020 was collected, including the source of the data. Please ensure that sufficient information is provided so that other researchers could potentially replicate these analyses.

3.We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: General comments –

• The manuscript needs editing for spell check, English and grammar.

• The control methods deployed in China should also be described considering that these were effective to get the R0 to <1 within a week. It may help other countries to streamline their strategies

Specific comments –

Sample size –

The authors have not described how the sample size was estimated? Was the study adequately powered to predict the outcomes? It is recommended that a post-hoc power analysis be undertaken to assess if study is also adequately powered to meet the study objectives.

Sampling strategy –

How or on what criteria, the sample was selected should be described? Was it representative of the other COVID-19 patients in terms of profile and severity?

Methods –

The authors have not specified what type of distribution their data followed (normal/uniform/discrete/triangular/Beta-PERT distribution), this will determine

how to output a random variable that follows a certain distribution. The authors should specify this and accordingly justify the method used. Did they use any of the data transformation methods? If so this should be specified

Results –

• As Monte Carlo method is a probabilistic method with randomness playing a role in predicting future outcomes, there will always be a margin of error related to the results. The authors should specify the margin of error and confidence probability of valid findings.

• What was the accuracy of this proposed new method to the existing methods for simulation to calculate R0 that the authors have described.

• Kindly describe how exactly can/must we define the inputs and model the underlying processes to use this proposed new method?

• It is recommended that tallying of Simulation results be done to establish reliability

Discussion

• Is the Monte Carlo method that uses a stochastic model to your data? should be discussed

• Discuss the accuracy of your proposed method study vis-à-vis the accuracy of other established methods.

• Strengths and Limitations of the study should be discussed

• Study is conducted in a small sub-set of Chinese population, limitations related to external generalizability should be discussed

Ethical considerations/obligations

The manuscript is silent about the ethical considerations/obligations.

• Was an approval taken from any ethics committee?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Feb 11;16(2):e0246715. doi: 10.1371/journal.pone.0246715.r002

Author response to Decision Letter 0


27 Sep 2020

Thank you very much for processing our manuscript entitled “Chinese Control Efficacy on COVID-19”, and thanks for all the valuable comments and suggestions, which provide the excellent guidance to improve our manuscript. Accordingly, we have largely revised the manuscript. Enclosed please find a detailed response to the referee report. For the sake of convenience, the main modifications are marked in red in the revised manuscript. We believe that the revised manuscript can meet the standard of PLoS ONE.

Attachment

Submitted filename: Reply.pdf

Decision Letter 1

Abdallah M Samy

12 Jan 2021

PONE-D-20-11733R1

Chinese Control Efficacy on COVID-19

PLOS ONE

Dear Dr. Zhou,

Thank you very much for submitting your manuscript "Chinese Control Efficacy on COVID-19" (#PONE-D-20-11733R1) for review by PLOS ONE. As with all papers submitted to the journal, your manuscript was fully evaluated by academic editor (myself) and by independent peer reviewers. The reviewers appreciated the attention to an important health topic, but they raised substantial concerns about the paper that must be addressed before this manuscript can be accurately assessed for meeting the PLOS ONE criteria. Therefore, if you feel these issues can be adequately addressed, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. We can’t, of course, promise publication at that time.

Please submit your revised manuscript by Feb 26 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Abdallah M. Samy, PhD

Academic Editor

PLOS ONE

Additional Editor Comments:

Please address carefully all our comments below. Thanks!

1. We note that the authors state in their abstract "The province-level analysis indicates that Chinese control measures on COVID-19 are very effective and efficient, that is, the effective reproduction numbers of the majority of provinces in mainland China got down to < 1 just by one week from the setting of control measures, and the temporal reproduction number of the week [15 Feb, 21 Feb] is only about 0.18" and also state in their discussion "The results indicate that Chinese control measures have achieved remarkable success..." and "The huge success of Chinese control measures on COVID-19 resulted from the ambitious and aggressive government-led actions." However, their study does not directly test whether specific control measures caused the reduction of R and new cases, and thus, we do not feel that these statements are supported by the rest of the study. To meet our publication criteria that conclusions are supported by the data

(https://journals.plos.org/plosone/s/criteria-for-publication#loc-4) we recommend that authors change these sentences to something such as:

Abstract:

"The province-level analysis indicates that the effective reproduction numbers of the majority of provinces in mainland China got down to < 1 just by one week from the setting of control measures, and the temporal reproduction number of the week [15 Feb, 21 Feb] is only about 0.18. It is therefore likely that Chinese control measures on COVID-19 were effective and efficient, though more research needs to be performed."

Discussion:

"Our results suggest that Chinese control measures have been effective..." and

"Government-led actions likely played a role in the reduction of new COVID-19 cases."

2. We also note that PLOS’ guidelines state that the title should be "specific, descriptive, concise, and comprehensible to readers outside the field" (https://journals.plos.org/plosone/s/submission-guidelines#loc-title). In this case, we feel that the title is vague and does not describe the methods or aims of the study. We suggest that the title include a reference to the methodology or component to be measured (i.e., temporal reproduction number), the aim of the study (i.e, evaluating the effect of implementing COVID-19 control measures on reproduction number"), and the locale that was studied (i.e., China). For example, a title such as "COVID-19 control measure implementation in China: estimating the effect on temporal reproduction number" would be appropriate.

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Feb 11;16(2):e0246715. doi: 10.1371/journal.pone.0246715.r004

Author response to Decision Letter 1


21 Jan 2021

We have revised the manuscript according to the editor's suggestions. For the sake of convenience, the main modifications are marked in red in the revised manuscript.

Attachment

Submitted filename: Reply-PONE-D-20-11733R1.pdf

Decision Letter 2

Abdallah M Samy

26 Jan 2021

Evaluating the effect of Chinese control measures on COVID-19 via temporal reproduction number estimation

PONE-D-20-11733R2

Dear Dr. Zhou,

We’re pleased to inform you that your manuscript, "Evaluating the effect of Chinese control measures on COVID-19 via temporal reproduction number estimation" (PONE-D-20-11733R2), has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Abdallah M. Samy, PhD

Academic Editor

PLOS ONE

Acceptance letter

Abdallah M Samy

1 Feb 2021

PONE-D-20-11733R2

Evaluating the effect of Chinese control measures on COVID-19 via temporal reproduction number estimation

Dear Dr. Zhou:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Abdallah M. Samy

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Dataset

    (RAR)

    Attachment

    Submitted filename: Reply.pdf

    Attachment

    Submitted filename: Reply-PONE-D-20-11733R1.pdf

    Data Availability Statement

    The detailed information of daily number of confirmed cases is from National Health Commission of China whose URL address is http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml. And all dataset files are available from email dbchen@uestc.edu.cn The authors of the present study had no special access privileges in accessing the datasets from the National Health Commission of China which other interested researchers would not have.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES